GlobeNewswire by notified

ERYTECH to Participate in the Upcoming April Investor Conferences

Share

ERYTECH to Participate in
theUpcomingAprilInvestor Conferences


Cambridge, MA (U.S.) and Lyon (France), March 28, 2022ERYTECH Pharma (Nasdaq & Euronext: ERYP), a clinical-stage biopharmaceutical company developing innovative therapies by encapsulating therapeutic drug substances inside red blood cells, today announced their participation in upcoming investor conferences and invites investors to participate in one-on-one meetings:

Investor Access Event

Link to the event

  • Date: Monday, April 4th and Tuesday, April 5th
  • Place: Paris (France)
  • Participant: Eric SOYER (CFO-COO)

Kempen 14th Life Sciences Conference

Link to the event

  • Date: Thursday, April 21st
  • Place: Amsterdam (Netherlands)
  • Participants: Gil BEYEN (CEO) and Eric SOYER (CFO-COO)

If you are interested in arranging a one-on-one meeting, please contact your conference representative.

About ERYTECH and eryaspase (GRASPA®)

ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS® platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival.

The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cells’ altered asparagine and glutamine metabolism. The proof of concept of eryaspase as a cancer metabolism agent was established in different trials in acute lymphoblastic leukemia (ALL) and pancreatic cancer. An investigator sponsored Phase 2 trial (IST) evaluating the use of eryaspase in ALL patients who developed hypersensitivity reactions to pegylated asparaginase recently reported positive results, based on which the Company intends to request approval in the United States and potentially other territories. The Company is also pursuing a Phase 1 investigator-sponsored clinical trial in first-line pancreatic cancer.

Eryaspase received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of advanced pancreatic cancer and treatment of acute lymphoblastic leukemia (ALL) patients who have developed hypersensitivity reactions to E. coli-derived pegylated asparaginase. The FDA and the European Medicines Agency have granted eryaspase orphan drug status for the treatment of pancreatic cancer and ALL.

ERYTECH produces its product candidates for treatment of patients in Europe at its GMP-approved manufacturing site in Lyon, France, and for patients in the United States at its GMP manufacturing site in Princeton, New Jersey, USA. Eryaspase is not an approved medicine.

ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.


For more information, please visit www.erytech.com

CONTACTS

ERYTECH
Eric Soyer
CFO & COO
NewCap
Mathilde Bohin / Louis-Victor Delouvrier
Investor relations
Nicolas Merigeau
Media relations


+33 4 78 74 44 38
investors@erytech.com


+33 1 44 71 94 94
erytech@newcap.eu



Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

PRESS RELEASE: NACON:  CARANTS*! DRAW CLOSER AND SEE THE FIRST IMAGES OF GREEDFALL 218.5.2022 08:00:00 CEST | Press release

CARANTS*! DRAW CLOSER AND SEE THE FIRST IMAGES OF GREEDFALL 2 Lesquin, 18 May 2022 – After the success of GreedFall, with over 2 million copies sold, NACON and the development studio Spiders are pleased to announce a new game: GreedFall 2. Continuing the winning formula of the first game, GreedFall 2 is an RPG that focuses on story and player choice but also includes new gameplay in the form of more tactical combat and revisits the unique universe created by its predecessor. The story starts three years before the events of the first game and the adventures of De Sardet. This time you play as a native of Teer Fradee, uprooted by force from your island and taken to the continent of Gacane, where the colonists are from. In this old world ravaged by war and scarred by the Malichor plague and the political scheming of the different factions, you must regain your freedom and control of your own destiny. Using diplomacy, cunning or combat, as well as help from allies you make, it's up to you

Millicom announces the terms of its rights offering18.5.2022 08:00:00 CEST | Press release

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO AUSTRALIA, CANADA, HONG KONG OR SINGAPORE OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE ADDITIONAL DOCUMENTS TO BE PREPARED OR REGISTERED OR REQUIRE ANY OTHER ACTIONS TO BE TAKEN. PLEASE REFER TO “IMPORTANT INFORMATION” AT THE END OF THIS PRESS RELEASE. Millicom announces the terms of its rights offering Luxembourg, May 18, 2022 – The board of directors of Millicom International Cellular S.A. (“Millicom”, the “Company” or “we”) has today, making use of the authorization provided for in the Company’s articles of association, resolved on a rights offering (the “Rights Offering”) granting preferential subscription rights to existing holders of sharesand Swedish Depositary Receipts (“SDRs”) to subscribe for up to 70,357,088 shares in aggregate (including in theform of SDRs) and hereby announces the terms of the Rights Offering.

AB Klaipėdos nafta (KN) will hold an Investor Conference Webinar to introduce unaudited financial results for the three months of 202218.5.2022 08:00:00 CEST | Press release

KN invites shareholders, investors, analysts, and other stakeholders to join its investor conference webinar scheduled on the May 27th of 2022 at 9.00 am (EET). The presentation will be held in English. The webinar will be hosted by KN Chief Executive Officer Darius Šilenskis and Chief Financial Officer Mindaugas Kvekšas who will introduce the performance and unaudited financial results of KN for the three months of 2022. After the presentation investors are welcome to ask questions. Due to limited webinar time, we encourage participants to send their questions before the webinar until May 25th to emilija.ivanauskaite@nasdaq.com How to join the webinar? To join the webinar, please register via following link:https://nasdaq.zoom.us/webinar/register/WN_aVz8e35rRqO1UC5O3WBp4AYou will be provided with the webinar link and instructions how to join successfully. When joining the webinar for the first time, you will be asked to download the plug-in which will take only few seconds. In case pl

Sampo plc’s share buybacks 17/05/202218.5.2022 07:30:00 CEST | Press release

SAMPO PLC STOCK EXCHANGE RELEASE 18/05/2022 at 08:30 am Sampo plc’s share buybacks 17/05/2022 On 17/05/2022 Sampo plc (business code 0142213-3, LEI 743700UF3RL386WIDA22) has acquired its own A shares (ISIN code FI0009003305) as follows: Sampo plc’s share buybacksAggregated daily volume (in number of shares)Daily weighted average price of the purchased shares*Market (MIC Code)28,56046.33AQEU41,30446.31CEUX10,74946.33TQEX61,23946.32XHELTOTAL141,85246.32 *rounded to two decimals On 30 March 2022, Sampo announced a share buyback programme of up to a maximum of EUR 250 million in compliance with the Market Abuse Regulation (EU) 596/2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052. The programme, which started on 31 March 2022, is based on the authorization granted by Sampo's Annual General Meeting on 19 May 2021. After the disclosed transactions, the company owns in total 4,961,994 Sampo A shares representing 0.92 per cent of the total number of shares in Sampo plc. Details